Drugs / HLA-G-CAR.BiTE allogeneic γδ T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06150885 | Sep 2024 → Jun 2027 expected | cancer | Ever Supreme Bio Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLA-G-CAR.BiTE allogeneic γδ T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06150885 ↗ |
| Modality | Cell therapy | “Allogeneic Chimeric Antigen Receptor (CAR) Gamma-Delta T Cells” NCT06150885 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT06150885 ↗ |